Uni-Bio Science Group Limited (HKG:0690)

Revenue by Segment

Financials in millions HKD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Chemical Pharmaceutical Products	199.76M	249.62M	257.87M	232.49M	146.67M
Chemical Pharmaceutical Products Growth	-19.97%	-3.20%	10.91%	58.52%	263.89%
Biological Pharmaceutical Products	386.45M	303.36M	226.85M	207.82M	206.74M
Biological Pharmaceutical Products Growth	27.39%	33.73%	9.16%	0.52%	22.71%
Total	586.21M	552.98M	484.72M	440.32M	353.41M
Total Growth	6.01%	14.08%	10.08%	24.59%	69.27%

Revenue by Geography

Financials in millions HKD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
The People's Republic of China (PRC)	586.21M	552.98M	484.72M	440.32M	353.41M
The People's Republic of China (PRC) Growth	6.01%	14.08%	10.08%	24.59%	69.27%
Total	586.21M	552.98M	484.72M	440.32M	353.41M
Total Growth	6.01%	14.08%	10.08%	24.59%	69.27%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 10, 2026

Data Sources Report a data error